We are live on ! Find out more
ACM

ACT Capital Management Portfolio holdings

AUM $153M
This Fund
S&P 500
This Quarter Est. Return
-15.2%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$138M
AUM Growth
-$54.6M
Cap. Flow
-$14.6M
Cap. Flow %
-10.54%
Top 10 Hldgs %
60.84%
Holding
122
New
13
Increased
15
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$2.49M
2
ADTN icon
Adtran
ADTN
+$2.33M
3
VIR icon
Vir Biotechnology
VIR
+$2.27M
4
SSYS icon
Stratasys
SSYS
+$1.84M
5
PUBM icon
PubMatic
PUBM
+$1.47M

Top Sells

Rank Stock Value
1
TRIL
Trillium Therapeutics Inc.
TRIL
+$8.18M
2
AFRM icon
Affirm
AFRM
+$2.92M
3
UPST icon
Upstart Holdings
UPST
+$2.87M
4
NUAN
Nuance Communications, Inc.
NUAN
+$2.06M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$1.81M

Sector Composition

Rank Sector Weight
1 Healthcare 81.55%
2 Technology 7%
3 Communication Services 4.59%
4 Consumer Discretionary 2.09%
5 Energy 2.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLRB icon
76
Cellectar Biosciences
CLRB
$20.1M
$144K 0.1%
725
– –
SQZ
77
DELISTED
SQZ Biotechnologies Company
SQZ
$143K 0.1%
16,000
-6,000
-27% -$73.5K
YCBD icon
78
cbdMD
YCBD
$6.19M
$135K 0.1%
347
+62
+22% +$36K
RNAZ icon
79
TransCode Therapeutics
RNAZ
$4.5M
– –
0
– –
YALA
80
Yalla Group
YALA
$815M
$91K 0.07%
13,500
– –
AVDL
81
DELISTED
Avadel Pharmaceuticals
AVDL
$85K 0.06%
10,500
– –
SDPI
82
DELISTED
Superior Drilling Products Inc.
SDPI
$79K 0.06%
107,500
-10,000
-9% -$10.5K
TCON
83
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$79K 0.06%
1,425
– –
SYRS
84
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$70K 0.05%
2,150
-3,100
-59% -$126K
BLRX
85
BioLineRX
BLRX
$11.8M
$56K 0.04%
688
– –
GTH
86
DELISTED
Genetron Holdings Limited ADS
GTH
$46K 0.03%
2,500
– –
ARAV
87
DELISTED
Aravive, Inc. Common Stock
ARAV
$22K 0.02%
10,000
-13,500
-57% -$44.9K
TMDX icon
88
Transmedics
TMDX
$2.64B
$19K 0.01%
1,000
– –
AVGR
89
DELISTED
Avinger, Inc. Common Stock
AVGR
$16K 0.01%
117
– –
APVO icon
90
Aptevo Therapeutics
APVO
$5.22M
– –
0
– –
ABNB icon
91
Airbnb
ABNB
$90.5B
$8K 0.01%
50
– –
GNCA
92
DELISTED
Genocea Biosciences, Inc.
GNCA
$6K ﹤0.01%
5,000
– –
ABEO icon
93
Abeona Therapeutics
ABEO
$388M
– –
-11,120
Closed -$311K
ACIU icon
94
AC Immune
ACIU
$233M
– –
-21,500
Closed -$144K
AFRM icon
95
Affirm
AFRM
$26.3B
– –
-24,500
Closed -$2.92M
ALDX icon
96
Aldeyra Therapeutics
ALDX
$96.5M
– –
-1,500
Closed -$13K
ALXO icon
97
ALX Oncology
ALXO
$258M
– –
-1,500
Closed -$111K
CHRS icon
98
Coherus Oncology
CHRS
$224M
– –
-6,500
Closed -$104K
CLF icon
99
Cleveland-Cliffs
CLF
$7.22B
– –
-3,200
Closed -$63K
CLGN icon
100
CollPlant Biotechnologies
CLGN
$5.86M
– –
-7,500
Closed -$127K
1 2 3
4
5

Similar funds

BCI
Blue Capital Inc Omaha, Nebraska $153M AUM 28.69% 1-Year Est. Return
APW
Atlantic Private Wealth Chapel Hill, North Carolina $153M AUM 15.75% 1-Year Est. Return
DAM
Doheny Asset Management Los Angeles, California $153M AUM 42.04% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $153M AUM 16.24% 1-Year Est. Return
RHAM
Round Hill Asset Management Pasadena, California $153M AUM 6.67% 1-Year Est. Return
RFN
Redwood Financial Network Solon, Ohio $153M AUM 17.17% 1-Year Est. Return
SGM
Sellaronda Global Management New York $152M AUM 2.1% 1-Year Est. Return
HWM
Horizons Wealth Management Asheville, North Carolina $152M AUM 9.43% 1-Year Est. Return

ACT Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, ACT Capital Management held 122 positions worth $138M, down 28% from $193M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

ACT Capital Management withdrew a net $14.6M in Q4 2021, closing 30 positions and reducing 28 holdings. Its most notable exit was Trillium Therapeutics Inc., an estimated $8.18M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 79% a quarter earlier, followed by Technology and Communication Services.

Against the trend, ACT Capital Management opened a new position in Meta Platforms (Facebook) worth $2.52M.

  • ACT Capital Management's largest Q4 2021 buy was Meta Platforms (Facebook): 7,500 shares worth $2.52M.
  • ACT Capital Management added most to Stratasys in Q4 2021, an estimated $1.84M increase.
  • ACT Capital Management's biggest Q4 2021 reduction was Upstart Holdings, cutting an estimated $2.87M.
  • ACT Capital Management fully exited Trillium Therapeutics Inc. in Q4 2021, selling an estimated $8.18M.
  • ACT Capital Management's ten largest holdings make up 61% of its $138M portfolio in Q4 2021.
  • ACT Capital Management opened 13 new positions and closed 30 in Q4 2021.
  • ACT Capital Management's portfolio value fell 28% quarter-over-quarter to $138M.

Based on ACT Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.